Skip to main content
. 2021 Mar 17;28(1):594–606. doi: 10.1080/10717544.2021.1898703

Figure 4.

Figure 4.

Evaluation of the antitumor activity in vitro. (A) Cell viability of the human A375 cells treated with free MET (x-axis). The viability of the A375 cells treated with MET, DOX, MET&DOX, FCA NP-loaded MET, FCA NP-loaded DOX, and FCA NP-loaded MET&DOX. (B) Cell viability of the human SK-MEL-28 cells treated with free MET (x-axis) and free DOX. The viability of the SK-MEL-28 cells treated with MET, DOX, MET&DOX, FCA NP-loaded MET, FCA NP-loaded DOX, and FCA NP-loaded MET&DOX. All values are presented as the mean ± SD. (C, D) TUNEL staining analysis of the human A375 and SK-MEL-28 cells after treatment with MET, DOX, MET&DOX, FCA NP-loaded MET, FCA NP-loaded DOX, and FCA NP-loaded MET&DOX. Scale bars: 50 μm. n = 6 for each group. CTL: FCA NPs, MET FCA NPs: FCA NP-loaded MET, DOX FCA NPs: FCA NP-loaded DOX, MET&DOX FCA NPs: FCA NP-loaded MET&DOX.